Status:
COMPLETED
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Lead Sponsor:
Bayer
Conditions:
Myocardial Infarction
Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels. Research...
Eligibility Criteria
Inclusion
- Aged ≥18 years
- Patients will be selected if they have at least two prescriptions for low-dose aspirin (75-100 mg) between 2008 and 2018 for either:
- Primary prevention of CVD This is defined as patients who have no history of CVD any time prior to initiation of low-dose aspirin treatment are presumed to use for primary CVD prevention
- Secondary prevention of CVD This is defined as patients who have a history of CVD any time prior to initiation of low-dose aspirin treatment
- Patients with at least two prescriptions of low-dose aspirin with a dosage of 75-100mg within the first year of the index date.
- Restricted to patients with observation for at least 12 months before and 12 after the index date.
Exclusion
- \- Prescription of low-dose aspirin in 12 months before the index date.
Key Trial Info
Start Date :
September 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2020
Estimated Enrollment :
99999 Patients enrolled
Trial Details
Trial ID
NCT04097912
Start Date
September 30 2019
End Date
November 15 2020
Last Update
November 5 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Germany
2
Many Locations
Multiple Locations, United Kingdom